JP2012532891A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012532891A5 JP2012532891A5 JP2012519794A JP2012519794A JP2012532891A5 JP 2012532891 A5 JP2012532891 A5 JP 2012532891A5 JP 2012519794 A JP2012519794 A JP 2012519794A JP 2012519794 A JP2012519794 A JP 2012519794A JP 2012532891 A5 JP2012532891 A5 JP 2012532891A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- individual
- vitamin
- thyroid
- iron
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 133
- 210000001685 thyroid gland Anatomy 0.000 claims description 63
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 58
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 50
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 29
- 229960000304 folic acid Drugs 0.000 claims description 29
- 235000019152 folic acid Nutrition 0.000 claims description 29
- 239000011724 folic acid Substances 0.000 claims description 29
- 229930003779 Vitamin B12 Natural products 0.000 claims description 28
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims description 28
- 235000019163 vitamin B12 Nutrition 0.000 claims description 28
- 239000011715 vitamin B12 Substances 0.000 claims description 28
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 26
- 229930003316 Vitamin D Natural products 0.000 claims description 26
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 26
- 239000011575 calcium Substances 0.000 claims description 26
- 229910052791 calcium Inorganic materials 0.000 claims description 26
- 235000019166 vitamin D Nutrition 0.000 claims description 26
- 239000011710 vitamin D Substances 0.000 claims description 26
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 26
- 229940046008 vitamin d Drugs 0.000 claims description 26
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims description 25
- 229910052742 iron Inorganic materials 0.000 claims description 25
- 229960005069 calcium Drugs 0.000 claims description 23
- YDTFRJLNMPSCFM-YDALLXLXSA-M levothyroxine sodium anhydrous Chemical compound [Na+].IC1=CC(C[C@H](N)C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 YDTFRJLNMPSCFM-YDALLXLXSA-M 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 18
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 claims description 13
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 claims description 8
- 206010002065 Anaemia megaloblastic Diseases 0.000 claims description 7
- 208000000682 Megaloblastic Anemia Diseases 0.000 claims description 7
- 231100001016 megaloblastic anemia Toxicity 0.000 claims description 7
- 206010002064 Anaemia macrocytic Diseases 0.000 claims description 6
- 201000006437 macrocytic anemia Diseases 0.000 claims description 6
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 claims description 4
- XUIIKFGFIJCVMT-LBPRGKRZSA-N L-thyroxine Chemical group IC1=CC(C[C@H]([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-LBPRGKRZSA-N 0.000 claims description 4
- LKYWLLWWYBVUPP-XOCLESOZSA-L Liotrix Chemical compound [Na+].[Na+].IC1=CC(C[C@H](N)C([O-])=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1.IC1=CC(C[C@H](N)C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 LKYWLLWWYBVUPP-XOCLESOZSA-L 0.000 claims description 4
- 102000009843 Thyroglobulin Human genes 0.000 claims description 4
- 108010034949 Thyroglobulin Proteins 0.000 claims description 4
- 239000002269 analeptic agent Substances 0.000 claims description 4
- 229940119099 cytomel Drugs 0.000 claims description 4
- 229940089517 levo-t Drugs 0.000 claims description 4
- 229950008325 levothyroxine Drugs 0.000 claims description 4
- 229960003918 levothyroxine sodium Drugs 0.000 claims description 4
- SBXXSUDPJJJJLC-YDALLXLXSA-M liothyronine sodium Chemical compound [Na+].IC1=CC(C[C@H](N)C([O-])=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 SBXXSUDPJJJJLC-YDALLXLXSA-M 0.000 claims description 4
- 229960002018 liothyronine sodium Drugs 0.000 claims description 4
- 229940099268 synthroid Drugs 0.000 claims description 4
- 229960002175 thyroglobulin Drugs 0.000 claims description 4
- -1 thyroid Natural products 0.000 claims description 4
- 229940034208 thyroxine Drugs 0.000 claims description 4
- 229940035722 triiodothyronine Drugs 0.000 claims description 4
- 229940055817 triostat Drugs 0.000 claims description 4
- 230000002285 radioactive effect Effects 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 8
- 229940065207 methylfolic acid Drugs 0.000 claims 8
- 201000010000 Agranulocytosis Diseases 0.000 claims 4
- 208000032467 Aplastic anaemia Diseases 0.000 claims 4
- 206010022971 Iron Deficiencies Diseases 0.000 claims 4
- 102000005954 Methylenetetrahydrofolate Reductase (NADPH2) Human genes 0.000 claims 4
- 108010030837 Methylenetetrahydrofolate Reductase (NADPH2) Proteins 0.000 claims 4
- 206010033661 Pancytopenia Diseases 0.000 claims 4
- 208000031845 Pernicious anaemia Diseases 0.000 claims 4
- 201000002364 leukopenia Diseases 0.000 claims 4
- 231100001022 leukopenia Toxicity 0.000 claims 4
- 208000004235 neutropenia Diseases 0.000 claims 4
- 206010043554 thrombocytopenia Diseases 0.000 claims 4
- 229940080162 levoxyl Drugs 0.000 claims 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 2
- 206010019670 Hepatic function abnormal Diseases 0.000 claims 2
- 208000036696 Microcytic anaemia Diseases 0.000 claims 2
- 206010029783 Normochromic normocytic anaemia Diseases 0.000 claims 2
- 239000011630 iodine Substances 0.000 claims 2
- 229910052740 iodine Inorganic materials 0.000 claims 2
- 208000037233 normocytic anemia Diseases 0.000 claims 2
- 230000005855 radiation Effects 0.000 claims 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims 1
- 231100001238 environmental toxicant Toxicity 0.000 claims 1
- 231100000317 environmental toxin Toxicity 0.000 claims 1
- 229940043671 antithyroid preparations Drugs 0.000 description 5
- 239000003200 antithyroid agent Substances 0.000 description 3
- 229940105150 5-methyltetrahydrofolic acid Drugs 0.000 description 2
- 230000003208 anti-thyroid effect Effects 0.000 description 2
- 208000003532 hypothyroidism Diseases 0.000 description 2
- 230000002989 hypothyroidism Effects 0.000 description 2
- ZNOVTXRBGFNYRX-ABLWVSNPSA-N levomefolic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZNOVTXRBGFNYRX-ABLWVSNPSA-N 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 206010016880 Folate deficiency Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 108090000445 Parathyroid hormone Proteins 0.000 description 1
- KNAHARQHSZJURB-UHFFFAOYSA-N Propylthiouracile Chemical compound CCCC1=CC(=O)NC(=S)N1 KNAHARQHSZJURB-UHFFFAOYSA-N 0.000 description 1
- CFOYWRHIYXMDOT-UHFFFAOYSA-N carbimazole Chemical compound CCOC(=O)N1C=CN(C)C1=S CFOYWRHIYXMDOT-UHFFFAOYSA-N 0.000 description 1
- 229960001704 carbimazole Drugs 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- AXZAYXJCENRGIM-UHFFFAOYSA-J dipotassium;tetrabromoplatinum(2-) Chemical compound [K+].[K+].[Br-].[Br-].[Br-].[Br-].[Pt+2] AXZAYXJCENRGIM-UHFFFAOYSA-J 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- PMRYVIKBURPHAH-UHFFFAOYSA-N methimazole Chemical compound CN1C=CNC1=S PMRYVIKBURPHAH-UHFFFAOYSA-N 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 229910001487 potassium perchlorate Inorganic materials 0.000 description 1
- 229960002832 potassium perchlorate Drugs 0.000 description 1
- 229960002662 propylthiouracil Drugs 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 229960002178 thiamazole Drugs 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27061509P | 2009-07-10 | 2009-07-10 | |
| US61/270,615 | 2009-07-10 | ||
| US27074109P | 2009-07-13 | 2009-07-13 | |
| US61/270,741 | 2009-07-13 | ||
| PCT/US2010/041631 WO2011006147A1 (en) | 2009-07-10 | 2010-07-09 | Methods and compositions for treating thyroid-related medical conditions with reduced folates |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015232702A Division JP2016047840A (ja) | 2009-07-10 | 2015-11-30 | 甲状腺関連の医学的状態を還元葉酸によって処置するための方法および組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012532891A JP2012532891A (ja) | 2012-12-20 |
| JP2012532891A5 true JP2012532891A5 (enExample) | 2013-08-29 |
| JP5940448B2 JP5940448B2 (ja) | 2016-06-29 |
Family
ID=43427658
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012519794A Active JP5940448B2 (ja) | 2009-07-10 | 2010-07-09 | 甲状腺関連の医学的状態を還元葉酸によって処置するための方法および組成物 |
| JP2015232702A Withdrawn JP2016047840A (ja) | 2009-07-10 | 2015-11-30 | 甲状腺関連の医学的状態を還元葉酸によって処置するための方法および組成物 |
| JP2017142887A Withdrawn JP2017186383A (ja) | 2009-07-10 | 2017-07-24 | 甲状腺関連の医学的状態を還元葉酸によって処置するための方法および組成物 |
| JP2019054748A Withdrawn JP2019089858A (ja) | 2009-07-10 | 2019-03-22 | 甲状腺関連の医学的状態を還元葉酸によって処置するための方法および組成物 |
| JP2021043527A Withdrawn JP2021091739A (ja) | 2009-07-10 | 2021-03-17 | 甲状腺関連の医学的状態を還元葉酸によって処置するための方法および組成物 |
| JP2023045339A Withdrawn JP2023068107A (ja) | 2009-07-10 | 2023-03-22 | 甲状腺関連の医学的状態を還元葉酸によって処置するための方法および組成物 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015232702A Withdrawn JP2016047840A (ja) | 2009-07-10 | 2015-11-30 | 甲状腺関連の医学的状態を還元葉酸によって処置するための方法および組成物 |
| JP2017142887A Withdrawn JP2017186383A (ja) | 2009-07-10 | 2017-07-24 | 甲状腺関連の医学的状態を還元葉酸によって処置するための方法および組成物 |
| JP2019054748A Withdrawn JP2019089858A (ja) | 2009-07-10 | 2019-03-22 | 甲状腺関連の医学的状態を還元葉酸によって処置するための方法および組成物 |
| JP2021043527A Withdrawn JP2021091739A (ja) | 2009-07-10 | 2021-03-17 | 甲状腺関連の医学的状態を還元葉酸によって処置するための方法および組成物 |
| JP2023045339A Withdrawn JP2023068107A (ja) | 2009-07-10 | 2023-03-22 | 甲状腺関連の医学的状態を還元葉酸によって処置するための方法および組成物 |
Country Status (26)
| Country | Link |
|---|---|
| US (13) | US8343974B2 (enExample) |
| EP (2) | EP2451299B1 (enExample) |
| JP (6) | JP5940448B2 (enExample) |
| KR (1) | KR101850558B1 (enExample) |
| CN (2) | CN105476997B (enExample) |
| AP (1) | AP2012006124A0 (enExample) |
| AU (1) | AU2010271178B2 (enExample) |
| BR (1) | BR112012000614B1 (enExample) |
| CA (2) | CA3031481C (enExample) |
| DK (1) | DK2451299T3 (enExample) |
| EA (1) | EA201270160A1 (enExample) |
| ES (1) | ES2569238T3 (enExample) |
| HR (1) | HRP20160406T1 (enExample) |
| HU (1) | HUE027341T2 (enExample) |
| IL (3) | IL304064A (enExample) |
| IN (1) | IN2012DN01286A (enExample) |
| MX (2) | MX2012000535A (enExample) |
| MY (2) | MY189270A (enExample) |
| NZ (1) | NZ598171A (enExample) |
| PH (2) | PH12022552212A1 (enExample) |
| PL (1) | PL2451299T3 (enExample) |
| SG (2) | SG177613A1 (enExample) |
| SI (1) | SI2451299T1 (enExample) |
| SM (1) | SMT201600110B (enExample) |
| WO (1) | WO2011006147A1 (enExample) |
| ZA (2) | ZA201201002B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2012000535A (es) | 2009-07-10 | 2012-03-29 | Linzy O Scott Iii | Métodos y composiciones para tratar afecciones médicas relacionadas con la tiroides con folatos reducidos. |
| US20140271704A1 (en) * | 2013-03-15 | 2014-09-18 | Jarrow Formulas, Inc. | METHODS OF PRODUCING NUTRITIONAL SUPPLEMENTS USING MUSHROOMS FROM THE SPECIES Poria cocos OR Flammulina velutipes |
| US20160053281A1 (en) * | 2013-08-15 | 2016-02-25 | The University Court Of The University Of Edinburgh | Enhanced Expression Of RNA Vectors |
| CN103705497B (zh) * | 2013-12-11 | 2015-04-01 | 武汉威立得生物医药有限公司 | 碘塞罗宁在制备治疗或预防流感病毒感染的药物中的应用 |
| JP6424078B2 (ja) * | 2014-02-13 | 2018-11-14 | 山洋電気株式会社 | ステータ、ステータの製造方法、およびモータ |
| CN108992458A (zh) * | 2018-06-12 | 2018-12-14 | 中国人民解放军第四军医大学 | 维生素b12用于制备预防和/或治疗术后认知功能障碍药物的应用 |
| IL297453A (en) * | 2020-04-22 | 2022-12-01 | Linzy O Scott Iii | Treatment of conditions related to thyroid hormone |
| WO2022023977A1 (en) * | 2020-07-27 | 2022-02-03 | Ayoub George | Methods of reducing incidence or risk of cerebral folate deficiency |
| WO2022208216A1 (en) * | 2021-03-31 | 2022-10-06 | Boggarapu, Shravya | An oral liquid formulation of metformin, teneligliptin, vitamin b12, atorvastatin and levothyroxine for diabetes |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4205126A (en) * | 1978-01-01 | 1980-05-27 | Cartaya Oscar A | Serum-free cell culture media |
| US5563126A (en) | 1986-11-20 | 1996-10-08 | Metabolite Laboratories | Method for treatment and prevention of deficiencies of vitamins B12, folic acid, and B6 |
| IT1229517B (it) | 1989-01-31 | 1991-09-03 | Bioresearch Spa | Impiego di acido 5-metiltetraidrofolico, di acido 5 formiltetraidrofolico, e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato adatte ad essere impiegate nella terapia dei disordini depressivi e composizioni farmaceutiche relative. |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| GB9022545D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Culture medium |
| US5591709A (en) | 1991-08-30 | 1997-01-07 | Life Medical Sciences, Inc. | Compositions and methods for treating wounds |
| US6207651B1 (en) | 1996-08-02 | 2001-03-27 | Metabolite Laboratories | Method for treatment and prevention of deficiencies of vitamins B12, folic acid, and B6 |
| US5795873A (en) | 1992-12-29 | 1998-08-18 | Metabolite Laboratories, Inc. | Method for treatment and prevention of deficiencies of vitamins B12, folic acid and B6 |
| US6455288B1 (en) | 1993-04-08 | 2002-09-24 | Dade Behring Marburg Gmbh | Homogeneous immunoassays using mutant glucose-6-phosphate dehydrogenases |
| CH686369A5 (de) | 1994-05-09 | 1996-03-15 | Eprova Ag | Stabile kristalline (6S)- und (6R)-Tetrahydrofolseure. |
| US5681561A (en) | 1995-06-07 | 1997-10-28 | Life Medical Sciences, Inc. | Compositions and methods for improving autologous fat grafting |
| EP0877563B1 (en) | 1996-01-31 | 2004-03-31 | South Alabama Medical Science Foundation | Food and vitamin preparations containing the natural isomer of reduced folates |
| CH693255A5 (de) | 1997-06-13 | 2003-05-15 | Eprova Ag | Verwendung von Tetrahydrofolaten in der natürlichenstereoisomeren Form zur Herstellung einer pharmazeutischenZubereitung geeignet zur Beeinflussung des Homocystein-Spiegels. |
| US6200950B1 (en) | 1998-02-18 | 2001-03-13 | Nestec S.A. | Calorically dense nutritional composition |
| US6153582A (en) | 1998-11-05 | 2000-11-28 | Bausch & Lomb Surgical, Inc. | Defined serumfree medical solution for ophthalmology |
| AU1853600A (en) | 1999-01-06 | 2000-07-24 | Choong-Chin Liew | Method for the detection of gene transcripts in blood and uses thereof |
| DE60011877D1 (de) | 1999-01-19 | 2004-08-05 | Lidia M Vallarino | Reaktionssystem und verfahren zur verstärkung der lumineszenz von makrocyclischen lanthanid(iii)-komplexen |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| WO2000061154A1 (en) * | 1999-04-08 | 2000-10-19 | Khan Airudin S | Composition, containing sublimed sulphur, for altering plasma homodyst(e) levels in humans |
| CH693905A5 (de) | 1999-04-15 | 2004-04-15 | Eprova Ag | Stabile kristalline Salze von 5-Methyltetrahydrofolsäure. |
| US8383081B2 (en) | 1999-05-10 | 2013-02-26 | Immunomedics, Inc. | Anti-CD74 immunoconjugates and methods of use |
| US6309663B1 (en) | 1999-08-17 | 2001-10-30 | Lipocine Inc. | Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
| US6720001B2 (en) | 1999-10-18 | 2004-04-13 | Lipocine, Inc. | Emulsion compositions for polyfunctional active ingredients |
| US20020042096A1 (en) | 2000-01-31 | 2002-04-11 | Rosen Craig A. | Nucleic acids, proteins, and antibodies |
| EP1372571A4 (en) | 2001-03-20 | 2006-06-07 | New Century Pharmaceuticals | METHOD AND COMPOSITIONS FOR OPTIMIZING THE STABILITY OF BLOOD AND TISSUES CONFERRED BY CAMPTOTHECIN AND OTHER THERAPEUTIC COMPOUNDS BINDING ALBUMIN |
| US6506413B1 (en) | 2001-04-30 | 2003-01-14 | Joseph C. Ramaekers | Compositions for treating animal diseases and syndromes |
| US20080220441A1 (en) | 2001-05-16 | 2008-09-11 | Birnbaum Eva R | Advanced drug development and manufacturing |
| AU2002322275A1 (en) | 2001-06-20 | 2003-01-08 | Mayo Foundation For Medical Education And Research | Adenosyl-cobalamin fortified compositions |
| US6660293B2 (en) | 2001-06-29 | 2003-12-09 | Everett Laboratories, Inc. | Compositions and methods for prophylactic and therapeutic supplementation of nutrition in subjects |
| US20030195253A1 (en) * | 2001-08-14 | 2003-10-16 | Franz G. Andrew | Unadsorbed levothyroxine pharmaceutical compositions, methods of making and methods of administration |
| US20040023961A1 (en) | 2002-02-11 | 2004-02-05 | Bayer Corporation | Aryl ureas with raf kinase and angiogenisis inhibiting activity |
| US7074426B2 (en) | 2002-03-27 | 2006-07-11 | Frank Kochinke | Methods and drug delivery systems for the treatment of orofacial diseases |
| WO2003105561A2 (en) | 2002-06-12 | 2003-12-24 | Surromed, Inc. | Method and devices for diagnosing and treating choroid plexus failure |
| AU2003300776A1 (en) | 2002-09-09 | 2004-05-25 | Omeros Corporation | G protein coupled receptors and uses thereof |
| CN101972478B (zh) | 2002-10-08 | 2012-10-31 | 免疫医疗公司 | 抗体治疗 |
| WO2004056311A2 (en) | 2002-12-17 | 2004-07-08 | Massachusetts Institute Of Technology | Stimuli-responsive systems for controlled drug delivery |
| US20050031651A1 (en) | 2002-12-24 | 2005-02-10 | Francine Gervais | Therapeutic formulations for the treatment of beta-amyloid related diseases |
| WO2004092334A2 (en) | 2003-04-09 | 2004-10-28 | Jarrow Formulas, Inc. | Methods of producing edible fungi containing activated folates and nutritional supplements containing activated folates |
| US7517342B2 (en) | 2003-04-29 | 2009-04-14 | Boston Scientific Scimed, Inc. | Polymer coated device for electrically medicated drug delivery |
| US20050031544A1 (en) | 2003-08-07 | 2005-02-10 | Njemanze Philip Chidi | Receptor mediated nanoscale copolymer assemblies for diagnostic imaging and therapeutic management of hyperlipidemia and infectious diseases |
| CN1921842A (zh) | 2003-12-24 | 2007-02-28 | 努特里奇亚有限公司 | 包含泛酸或其衍生物的组合物及其刺激食欲的应用 |
| US20060211752A1 (en) | 2004-03-16 | 2006-09-21 | Kohn Leonard D | Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression |
| JP2007535565A (ja) | 2004-04-30 | 2007-12-06 | バイエル ファーマシューティカルス コーポレーション | 癌の治療に有用な置換ピラゾリル尿素誘導体 |
| US20100087546A1 (en) | 2005-04-20 | 2010-04-08 | Biogenic Innovations, Llc | Use of dimethyl sulfone (msm) to reduce homocysteine levels |
| US20060252049A1 (en) | 2005-05-04 | 2006-11-09 | Shuler Richard O | Growth-promoting and immunizing subcutaneous implant |
| WO2006119589A2 (en) * | 2005-05-11 | 2006-11-16 | Ramaekers, Vincent | Prevention and therapy of cerebral folate deficiency |
| EP1912641B1 (en) * | 2005-06-21 | 2019-07-24 | South Alabama Medical Science Foundation | Methods and compositions containing natural folates for protecting against radiation damage |
| RU2005128993A (ru) | 2005-09-08 | 2007-03-20 | Общество С Ограниченной Ответственностью Исследовательский Центр "Комкон" (Ru) | Средство для коррекции стресс-индуцируемых нейромедиаторных, нейроэндокринных и метаболических нарушений, а также способ профилактики и лечения сопутствующих им паталогических состояний |
| KR20080068679A (ko) | 2005-10-07 | 2008-07-23 | 더 유니버시티 오브 알라바마 | 활성 약학적, 생물학적, 영양학적 및 에너지적 조성의다형성 극복 및 향상된 특성 부여를 위한 다관능성 이온성액체 조성물 |
| WO2007070983A1 (en) | 2005-12-22 | 2007-06-28 | Apollo Life Sciences Limited | Transdermal delivery of pharmaceutical agents |
| US8524454B2 (en) | 2006-04-07 | 2013-09-03 | The Research Foundation Of State University Of New York | Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency |
| US20080066739A1 (en) | 2006-09-20 | 2008-03-20 | Lemahieu Edward | Methods and systems of delivering medication via inhalation |
| US20090088404A1 (en) | 2007-01-31 | 2009-04-02 | Methylation Sciences International Srl | Extended Release Pharmaceutical Formulations of S-Adenosylmethionine |
| BRPI0820943A2 (pt) | 2007-12-17 | 2015-06-30 | Lux Innovate Ltd | Composições e métodos para monitorização de fluxo através de sistemas de condução e contenção de fluido |
| MX2012000535A (es) * | 2009-07-10 | 2012-03-29 | Linzy O Scott Iii | Métodos y composiciones para tratar afecciones médicas relacionadas con la tiroides con folatos reducidos. |
-
2010
- 2010-07-09 MX MX2012000535A patent/MX2012000535A/es unknown
- 2010-07-09 CA CA3031481A patent/CA3031481C/en active Active
- 2010-07-09 SI SI201031168A patent/SI2451299T1/sl unknown
- 2010-07-09 IL IL304064A patent/IL304064A/en unknown
- 2010-07-09 US US12/833,933 patent/US8343974B2/en active Active
- 2010-07-09 NZ NZ598171A patent/NZ598171A/en unknown
- 2010-07-09 JP JP2012519794A patent/JP5940448B2/ja active Active
- 2010-07-09 MY MYPI2017000769A patent/MY189270A/en unknown
- 2010-07-09 ES ES10797960.1T patent/ES2569238T3/es active Active
- 2010-07-09 CN CN201510784785.0A patent/CN105476997B/zh active Active
- 2010-07-09 CA CA2804265A patent/CA2804265C/en active Active
- 2010-07-09 MX MX2014011635A patent/MX350564B/es unknown
- 2010-07-09 AU AU2010271178A patent/AU2010271178B2/en active Active
- 2010-07-09 KR KR1020127003358A patent/KR101850558B1/ko active Active
- 2010-07-09 EA EA201270160A patent/EA201270160A1/ru unknown
- 2010-07-09 PL PL10797960.1T patent/PL2451299T3/pl unknown
- 2010-07-09 AP AP2012006124A patent/AP2012006124A0/xx unknown
- 2010-07-09 MY MYPI2012000089A patent/MY181956A/en unknown
- 2010-07-09 DK DK10797960.1T patent/DK2451299T3/en active
- 2010-07-09 EP EP10797960.1A patent/EP2451299B1/en active Active
- 2010-07-09 BR BR112012000614-2A patent/BR112012000614B1/pt active IP Right Grant
- 2010-07-09 WO PCT/US2010/041631 patent/WO2011006147A1/en not_active Ceased
- 2010-07-09 SG SG2012002069A patent/SG177613A1/en unknown
- 2010-07-09 CN CN201080040828.XA patent/CN102639009B/zh active Active
- 2010-07-09 SG SG10201404000RA patent/SG10201404000RA/en unknown
- 2010-07-09 EP EP16154294.9A patent/EP3053583B1/en active Active
- 2010-07-09 PH PH1/2022/552212A patent/PH12022552212A1/en unknown
- 2010-07-09 HR HRP20160406TT patent/HRP20160406T1/hr unknown
- 2010-07-09 HU HUE10797960A patent/HUE027341T2/en unknown
- 2010-07-09 IL IL256966A patent/IL256966B2/en unknown
-
2012
- 2012-01-05 IL IL217401A patent/IL217401A0/en unknown
- 2012-02-10 ZA ZA2012/01002A patent/ZA201201002B/en unknown
- 2012-02-10 IN IN1286DEN2012 patent/IN2012DN01286A/en unknown
- 2012-11-28 US US13/687,109 patent/US8575171B2/en active Active
-
2013
- 2013-02-14 ZA ZA2013/01167A patent/ZA201301167B/en unknown
- 2013-10-01 US US14/043,309 patent/US9248130B2/en active Active
-
2015
- 2015-11-30 JP JP2015232702A patent/JP2016047840A/ja not_active Withdrawn
-
2016
- 2016-01-05 US US14/988,042 patent/US20160158237A1/en not_active Abandoned
- 2016-04-18 SM SM201600110T patent/SMT201600110B/it unknown
-
2017
- 2017-07-19 US US15/654,088 patent/US20170319589A1/en not_active Abandoned
- 2017-07-24 JP JP2017142887A patent/JP2017186383A/ja not_active Withdrawn
-
2018
- 2018-03-01 US US15/909,639 patent/US20180185373A1/en not_active Abandoned
- 2018-10-29 US US16/173,110 patent/US20190060318A1/en not_active Abandoned
-
2019
- 2019-03-07 PH PH12019500495A patent/PH12019500495A1/en unknown
- 2019-03-22 JP JP2019054748A patent/JP2019089858A/ja not_active Withdrawn
- 2019-06-21 US US16/448,663 patent/US20190307756A1/en not_active Abandoned
-
2020
- 2020-01-31 US US16/778,629 patent/US20200163969A1/en not_active Abandoned
- 2020-09-18 US US17/025,552 patent/US20210000836A1/en not_active Abandoned
-
2021
- 2021-03-17 JP JP2021043527A patent/JP2021091739A/ja not_active Withdrawn
- 2021-05-03 US US17/306,291 patent/US20210252002A1/en not_active Abandoned
-
2022
- 2022-07-22 US US17/871,243 patent/US20220354853A1/en not_active Abandoned
-
2023
- 2023-03-03 US US18/116,967 patent/US20230201204A1/en not_active Abandoned
- 2023-03-22 JP JP2023045339A patent/JP2023068107A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012532891A5 (enExample) | ||
| IL304064A (en) | Methods and compositions for the treatment of diseases related to the thyroid gland, with a reduced amount of folates | |
| HRP20200777T1 (hr) | Formulacije koje sadrže triazinone i željezo | |
| JP2017507973A5 (enExample) | ||
| JP2017527623A5 (enExample) | ||
| RU2010136914A (ru) | Средство и продукт питания для профилактики/уменьшения проявлений функционального расстройства пищеварения | |
| BR112012026223A2 (pt) | formulação adequada para o uso em ração animal, uso, e ração para animais. | |
| JP2010522240A (ja) | 炎症を処置するための組成物および方法 | |
| FI3355889T3 (fi) | Diaminopyrimidiini-p2x3- ja p2x2/3-reseptorimodulaattoreita käytettäväksi yskän hoidossa | |
| EA200802398A1 (ru) | Гранулы липоевой кислоты | |
| ATE487720T1 (de) | 5,6,7,8-tetrahydropteridin-derivate als hsp90- hemmer | |
| ZA201901370B (en) | Formulations for oral administration of active agents | |
| Saeed et al. | Lead poisoning: A persistent health hazard-general and oral aspects | |
| DE102007053369A1 (de) | Verwendung einer eine Kreatin-Komponente enthaltende Zusammensetzung zur Verbesserung der männlichen Fruchtbarkeit | |
| EA023535B9 (ru) | Композиция водного радиопротекторного фармацевтического раствора и способ предотвращения, снижения или исключения эффектов ионизирующей радиации | |
| UA90893C2 (ru) | Пероральная дозированная форма производных гемцитабина | |
| BRPI0715609A2 (pt) | Composto, uso de um composto, métodos para produzir um efeito antiproliferativo em um animal de sangue quente, e para tratar uma doença em um animal de sangue quente, e, composição farmacêutica | |
| JP2017012144A5 (enExample) | ||
| JP2016210757A5 (enExample) | ||
| MX2022013901A (es) | Composicion para la prevencion y el tratamiento de estados carenciales de folato y/o de vitamina b12, en particular la hiperhomocisteinemia. | |
| EA200900077A1 (ru) | Противоопухолевая, антибактериальная и антивирусная фармацевтическая композиция (ее варианты) | |
| Dickson et al. | The premature invocation of a ‘gut-lung axis’ may obscure the direct effects of respiratory microbiota on pneumonia susceptibility | |
| HRP20230735T1 (hr) | Betahistin, ili njegova farmaceutski prihvatljiva sol, i inhibitor monoamin oksidaze, za uporabu u liječenju ili prevenciji jednog ili više simptoma vrtoglavice kod subjekta | |
| AU2018251094B2 (en) | Compositions and methods that attenuate cognitive aging in individuals who do not have dementia | |
| US20150157585A1 (en) | Pharmaceutical compositions |